Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Other

Kyowa Hakko Kogyo Kabushiki Kaisha

Kyowa Kirin Co., Ltd.

Yutaka Kanda

Nobuo Hanai

Motoo Yamasaki

Kazuyasu Nakamura

Emi Hosaka

Kazuhisa Uchida

Toyohide Shinkawa

Naoko Yamane

Mitsuo Satoh

Kazuya Yamano

Hideharu Anazawa

Susumu Imabeppu

Makoto Morimoto

Tadashi Ashizawa

Shinji Nara

Masaji Kasai

Yutaka Saitoh

Hiromitsu Saito

Hitoshi Arai

Shun-ichi Ikeda

Takayuki Nakashima

Hiroshi Sano

Shiro Akinaga

Eiji Kobayashi

Yukimasa Shiotsu

Tsutomu Akama

Mitsunobu Hara

Hiroyuki Yamaguchi

Yoshinori Yamashita

Chikara Murakata

Katsushige Gomi

Tamio Mizukami

Motomichi Kono

Shiro Soga

Keiko Kawashima

Hiromi Ando

Hiroshi Nakagawa

Jiro Kajita

Katsuhiro Mori

Hirofumi Nakano

Akira Asai

Tatsuya Tamaoki

Kenichi Mochida

Fumihiko Kanai

Isami Takahashi

Yoichi Uosaki

Satoru Nagamura

Tomoki Naoe

Youichi Uosaki

Tsuyoshi Yamada

Hitoshi Kiyoi

Yoshihisa Ohta

Yushi Kitamura

Jun-ichi Saito

Kazuhito Akasaka

Hiroyuki Nagata

Motoki Miyama

Atsuhiro Hasegawa

Hiroshi Umehara

Rieko Nakatsu

Jun Eishima

Harumi Ue

Takeshi Takahashi

Hiroshi Sato

Richard L Tolman

Yutaka Saito

Akiko Furuya

Timothy A Grese

Tsuguo Kubota

Timothy S Powers

Mieczyslaw A Piatyszek

Tsutomu Agatsuma

Douglas Linn Gernert

Allison C Chin

Ryan Holcomb

Akifumi Kato

Takamasa Sugita

Shingo Kakita

Masayo Suzuki

Yuichi Takahashi

Emi Shoji

Tohru Yasuzawa

Hisashi Tagaya

Naoko Hiura

Junji Kanazawa

Yoko Takata

Masami Hamano

Yuko Uosaki

Upinder Singh

Kaori Endo

Rieko Tanaka

David A Johnson

Shinpei Yamaguchi

Kazuyo Sugiyama

Tomoyuki Nakazato

Hiroaki Nakamura

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Antibody composition-producing cell

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Method of modulating the activity of functional immune molecules

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

Anti-CD27 antibody

A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as 'RAGE') than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

Recombinant protein S composition

The present invention relates to a cell and mammal in which GDP-mannose 4,6-dehydratase is knocked-out. The cell and mammal are useful for the production of an antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, such as an antibody useful for treating various diseases. The cell and mammal are also useful for the production of a fragment of the antibody, and a fusion protein having the Fc region of the antibody.

Cells with altered fucosylation and producing antibodies therefrom

A cell in which the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is more decreased or deleted than its parent cell; a process for producing an antibody composition using the cell; a transgenic non-human animal or plant or the progenies thereof, in which genome is modified so as to have a decreased or deleted activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body; a process for producing an antibody composition from the animal or plant; and a medicament comprising the antibody composition.

Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost

Glycoengineered, recombinant antibody

The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody

The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation

Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase

Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation

Growing community of inventors

Machida, Japan

Yutaka Kanda